Rabbit as an animal model for pharmacokinetics studies of enteric capsule contains recombinant human keratinocyte growth factor loaded chitosan nanoparticles

Background: Recombinant human keratinocyte growth factor (rHuKGF) has gained considerable attention by researchers as epithelial cells proliferating agent. Moreover, intravenous truncated rHuKGF (palifermin) has been approved by Food and Drug Administration (FDA) to treat and prevent chemotherapy-in...

Full description

Bibliographic Details
Main Authors: Cheah, S.-C (Author), Elumalai, M. (Author), Kumar, P.V (Author), Majeed, A.B.B.A (Author), Maki, M.A.A (Author), Raghavan, B. (Author), Tatt, L.M (Author), Wei, Y.S (Author)
Format: Article
Language:English
Published: Bentham Science Publishers 2019
Subjects:
pH
Online Access:View Fulltext in Publisher
View in Scopus
LEADER 05786nam a2201093Ia 4500
001 10.2174-1574884714666181120103907
008 220121s2019 CNT 000 0 und d
020 |a 15748847 (ISSN) 
245 1 0 |a Rabbit as an animal model for pharmacokinetics studies of enteric capsule contains recombinant human keratinocyte growth factor loaded chitosan nanoparticles 
260 0 |b Bentham Science Publishers  |c 2019 
650 0 4 |a Administration, Oral 
650 0 4 |a animal 
650 0 4 |a animal cell 
650 0 4 |a animal experiment 
650 0 4 |a Animals 
650 0 4 |a Article 
650 0 4 |a bioavailability 
650 0 4 |a Bioavailability 
650 0 4 |a biological activity 
650 0 4 |a Biological Availability 
650 0 4 |a cell proliferation 
650 0 4 |a Cell Proliferation 
650 0 4 |a cell transport 
650 0 4 |a chitosan 
650 0 4 |a Chitosan 
650 0 4 |a chitosan nanoparticle 
650 0 4 |a Chitosan nanoparticles 
650 0 4 |a controlled study 
650 0 4 |a copolymer 
650 0 4 |a drug absorption 
650 0 4 |a drug blood level 
650 0 4 |a drug carrier 
650 0 4 |a Drug Carriers 
650 0 4 |a Drug Compounding 
650 0 4 |a drug delivery system 
650 0 4 |a drug effect 
650 0 4 |a drug formulation 
650 0 4 |a drug release 
650 0 4 |a drug solubility 
650 0 4 |a enteric coated tablet 
650 0 4 |a female 
650 0 4 |a FHs 74 Int cell line 
650 0 4 |a Fibroblast Growth Factor 7 
650 0 4 |a Fluorescence imaging 
650 0 4 |a fluorescence microscopy 
650 0 4 |a gelation 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a in vitro study 
650 0 4 |a incubation time 
650 0 4 |a Intestinal Absorption 
650 0 4 |a intestine absorption 
650 0 4 |a keratinocyte growth factor 
650 0 4 |a Leporidae 
650 0 4 |a Methacrylates 
650 0 4 |a methacrylic acid 
650 0 4 |a methacrylic acid methyl ester 
650 0 4 |a methylmethacrylate-methacrylic acid copolymer 
650 0 4 |a MTT assay 
650 0 4 |a mucoadhesion 
650 0 4 |a nanoparticle 
650 0 4 |a Nanoparticles 
650 0 4 |a nonhuman 
650 0 4 |a oral drug administration 
650 0 4 |a pH 
650 0 4 |a pharmacokinetic parameters 
650 0 4 |a Pharmacokinetics 
650 0 4 |a physiology 
650 0 4 |a polymethacrylic acid derivative 
650 0 4 |a Polymethacrylic Acids 
650 0 4 |a priority journal 
650 0 4 |a process optimization 
650 0 4 |a Proliferation 
650 0 4 |a Protein delivery 
650 0 4 |a Rabbits 
650 0 4 |a Recombinant human keratinocyte growth factor 
650 0 4 |a recombinant keratinocyte growth factor 
650 0 4 |a recombinant protein 
650 0 4 |a Recombinant Proteins 
650 0 4 |a rhodamine 
650 0 4 |a single drug dose 
650 0 4 |a Tablets, Enteric-Coated 
856 |z View Fulltext in Publisher  |u https://doi.org/10.2174/1574884714666181120103907 
856 |z View in Scopus  |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075192429&doi=10.2174%2f1574884714666181120103907&partnerID=40&md5=54cece4da79c20e6f5e0b8d3f42c56c5 
520 3 |a Background: Recombinant human keratinocyte growth factor (rHuKGF) has gained considerable attention by researchers as epithelial cells proliferating agent. Moreover, intravenous truncated rHuKGF (palifermin) has been approved by Food and Drug Administration (FDA) to treat and prevent chemotherapy-induced oral mucositis and small intestine ulceration. The labile structure and short circulation time of rHuKGF in-vivo are the main obstacles that reduce the oral bioactivity and dosage of such proteins at the target site. Objective: Formulation of methacrylic acid-methyl methacrylate copolymer-coated capsules filled with chitosan nanoparticles loaded with rHuKGF for oral delivery. Methods: We report on chitosan nanoparticles (CNPs) with diameter < 200 nm, prepared by ionic gelation, loaded with rHuKGF and filled in methacrylic acid-methyl methacrylate copolymer-coated capsules for oral delivery. The pharmacokinetic parameters were determined based on the serum levels of rHuKGF, following a single intravenous (IV) or oral dosages using a rabbit model. Furthermore, fluorescent microscope imaging was conducted to investigate the cellular uptake of the rhodamine-labelled rHuKGF-loaded nanoparticles. The proliferation effect of the formulation on FHs 74 Int cells was studied as well by MTT assay. Results: The mucoadhesive and absorption enhancement properties of chitosan and the protective effect of methacrylic acid-methyl methacrylate copolymer against rHuKGF release at the stomach, low pH, were combined to promote and ensure rHuKGF intestinal delivery and increase serum levels of rHuKGF. In addition, in-vitro studies revealed the protein bioactivity since rHuKGF-loaded CNPs significantly increased the proliferation of FHs 74 Int cells. Conclusion: The study revealed that oral administration of rHuKGF–loaded CNPs in methacrylic acid-methyl methacrylate copolymer-coated capsules is practically alternative to the IV administration since the absolute bioavailability of the orally administered rHuKGF–loaded CNPs, using the rabbit as animal model, was 69%. Fluorescent microscope imaging revealed that rhodamine-labelled rHuKGF-loaded CNPs were taken up by FHs 74 Int cells, after 6 hours’ incubation time, followed by increase in the proliferation rate. © 2019 Bentham Science Publishers 
700 1 0 |a Cheah, S.-C.  |e author  
700 1 0 |a Elumalai, M.  |e author  
700 1 0 |a Kumar, P.V.  |e author  
700 1 0 |a Majeed, A.B.B.A.  |e author  
700 1 0 |a Maki, M.A.A.  |e author  
700 1 0 |a Raghavan, B.  |e author  
700 1 0 |a Tatt, L.M.  |e author  
700 1 0 |a Wei, Y.S.  |e author  
773 |t Current Clinical Pharmacology  |x 15748847 (ISSN)  |g 14 2, 132-140